Ticker brief
ABVX ABIVAX SA-ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$113.35
1 day
-0.8%
14 days
-4.7%
mkt cap
$11.5B
signals 14d
12
authors 14d
4
crowd 14d
-0.9σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 66% cheap · 17 pctile own 1y | IV/HV 1.65× (as of 2026-07-31) |
| Skew — 25Δ RR 30d | -0.031 15 pctile own 1y | puts bid vs calls (downside bid) |
| Net dealer OI (NDOI) | +7.51 elevated | 5-session Δ -1.30 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2026-07-01 (z=2.5) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now -0.15 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 6 | -0.37 |
| @semodough | C | -3.01 | 3 | +0.12 |
| @LogicalThesis | A | +2.21 | 2 | +0.40 |
| @MrMojoRisinX | A | -0.23 | 1 | +0.35 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @bioinvestor24 | -0.15 | Frames SYRE as a broad platform positioned to compete with major immunology companies and exceed peer disease breadth. | — | tweet ↗ |
| 2026-08-26 | @semodough | +0.65 | Concludes Abivax is undervalued after reading reports on Spyre. | -2.7% | tweet ↗ |
| 2026-08-25 | @semodough | -0.15 | Reports ABVX short positioning increased by 15%. | -3.9% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | -0.65 | Calls ABVX fairly valued, boring and delusional after its earlier opportunity passed. | -2.4% | tweet ↗ |
| 2026-08-24 | @bioinvestor24 | -0.65 | Strongly favors MRNA's technology while criticizing ABVX longs and its unclear mechanism. | -2.4% | tweet ↗ |
| 2026-08-22 | @LogicalThesis | +0.00 | Cites historical pre-readout prices for ABVX and NKTR without a current stance. | -1.4% | tweet ↗ |
| 2026-08-21 | @LogicalThesis | +0.80 | Recaps another trader's successful 10-bagger pitches and the author's borrowed conviction. | -1.4% | tweet ↗ |
| 2026-08-21 | @semodough | -0.15 | Notes an unusual red Friday close while saying sentiment has not reversed. | -1.4% | tweet ↗ |
| 2026-08-20 | @MrMojoRisinX | +0.35 | Argues ABVX's sale process offers favorable hedged reward-risk despite forced selling and unwind pressure. | -4.1% | tweet ↗ |
| 2026-08-20 | @bioinvestor24 | -0.35 | Calls Moderna's positive interim oncology data a platform breakthrough while dismissing SMMT and ABVX approaches. | -4.1% | tweet ↗ |
| 2026-08-19 | @bioinvestor24 | -0.60 | Says cancer-risk concerns and market capitalization make ABVX difficult to acquire. | -6.0% | tweet ↗ |
| 2026-08-15 | @bioinvestor24 | +0.20 | Author doubts KLRA's data advantage while noting ABVX phase-2 data looked acceptable in retrospect. | -4.7% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.